ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Antioxidant treatment could halt neurodegeneration in early Parkinson's

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

 
Print Page
Email Article

Pfizer Inc. Plans Major Study to Determine Whether Celebrex Increases Heart Attack and Stroke Risk

  [ 164 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 20, 2004


CBS/AP) Pfizer Inc. plans a major study to see if its anti-arthritis medication, Celebrex, increases the risk of heart attack and stroke. The announcement comes three weeks after Merck & Co. pulled Vioxx, a rival arthritis medication, from the market because the drug doubled the risk of heart attack and strokes in patients taking the medication longer than 18 months.

Celebrex and Vioxx are both in a class of drugs called cox-2 inhibitors. Last week, Pfizer said a study showed that Bextra, another cox-2 inhibitor it sells, increased the risk of heart attacks in patients that had coronary bypass operations. In a related development, a top U.S. Food and Drug Administration official said new pain relievers in the same class as Vioxx and Celebrex face increased scrutiny because scientists do not have a full comprehension of how exactly they work in the body.

Acting FDA deputy commissioner Dr. Janet Woodcock also said the agency would hold an advisory committee meeting early next year to discuss safety of the drugs known as cox-2 inhibitors. "We are far from understanding the complex mechanisms that lead to this toxicity," said Woodcock, who was speaking at the American College of Rheumatology's annual meeting in San Antonio.

Woodcock's statements don't bode well for Whitehouse Station, N.J.-based Merck, which has another cox-2 inhibitor called Arcoxia currently under review at the FDA. The agency is slated to rule on whether to approve the drug by Oct. 30. Woodcock said the FDA will examine the length and size of the safety data drug companies offer when deciding whether to approve a new cox-2.

Analysts don't believe Merck has enough long-term data to establish that Arcoxia has a safe cardiovascular profile. In a statement, Pfizer said that in completed studies and ongoing trials, Celebrex has proven to be safe and also has shown it could help patients with cardiovascular disease. The study, which is expected to begin next year, will enroll more than 4,000 patients around the world.

©MMIV, CBS Broadcasting Inc. All Rights Reserved.



Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Vitamin D3 Extreme™ Optimized Curcumin Longvida®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

The Curcumin Revolution: 'Golden' Ticket to Better Health The Curcumin Revolution: 'Golden' Ticket to Better Health
When a Good Night's Sleep Is Just a Daydream... When a Good Night's Sleep Is Just a Daydream...
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask
Fighting Fatigue with Ground-breaking French Oak Wood Extract Fighting Fatigue with Ground-breaking French Oak Wood Extract

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map